Collegium Pharmaceutical Reports Record Q2 2025 Revenue, Raises Outlook and Initiates $150M Share Repurchase Program

Collegium Pharmaceutical reported Q2 2025 revenue of $188.0 million, up 29% YoY, driven by Jornay PM sales of $32.6 million and a 7% increase in the pain portfolio. The company raised its annual revenue guidance to $745-$760 million and announced a $150 million share repurchase program. Adjusted EBITDA is expected to rise to $440-$455 million.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter ended June 30, 2025, showing a robust performance driven by significant growth across its key product lines. The company generated a record quarterly net revenue of $188.0 million, up 29% year-over-year (YoY) [1].

Key highlights include:

- Jornay PM® Net Revenue: The company reported $32.6 million in net revenue for Jornay PM, a 23% YoY increase. This was accompanied by a 23% YoY growth in prescriptions, reaching an all-time high of over 26,000 healthcare providers writing prescriptions [1].
- Pain Portfolio: The pain portfolio generated $155.4 million in net revenue, up 7% YoY. Individual products within the portfolio saw varying levels of growth, with Belbuca® up 1%, Xtampza® ER up 18%, and Nucynta® Franchise up 4% [1].
- Full-Year Guidance: Collegium raised its full-year 2025 net revenue guidance to $745 to $760 million and its adjusted EBITDA guidance to $440 to $455 million [1].
- Share Repurchase Program: The company's Board of Directors authorized a new share repurchase program to repurchase up to $150 million of common stock through December 31, 2026 [1].

Collegium's President and Chief Executive Officer, Vikram Karnani, commented, "We continued to generate strong momentum in the second quarter, driven by sustained execution across our three strategic priorities, including record revenue from Jornay PM, maximizing our pain portfolio, and strategically deploying capital to enhance shareholder value." Chief Financial Officer, Colleen Tupper, added, "We delivered another impressive quarter characterized by record quarterly revenue, robust adjusted EBITDA, and significant cash flow generation, leading us to increase our 2025 financial guidance."

The company will participate in several upcoming investor conferences, including the Piper Sandler CNS Symposium and the Morgan Stanley 23rd Annual Global Healthcare Conference, to discuss its financial performance and strategic initiatives.

References:
[1] https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-second-quarter-2025-financial-results-raises